Showing 4561-4570 of 20465 results for "".
- Aglatimagene Besadenovec Plus Radiotherapy in Localized Prostate Cancerhttps://reachmd.com/news/aglatimagene-besadenovec-plus-radiotherapy-in-localized-prostate-cancer/2487557/Key Takeaways Longer disease-free survival was observed with aglatimagene besadenovec added to radiotherapy than with placebo. The phase 3, randomized, double-blind, placebo-controlled trial delivered CAN-2409 intraprostatically alongside radiotherapy.
- TENS Lowers Movement-Evoked Pain in Fibromyalgia Trialhttps://reachmd.com/news/tens-lowers-movement-evoked-pain-in-fibromyalgia-trial/2487562/Key Takeaways By day 60, lower movement-evoked pain was observed with PT plus TENS than with PT alone, with the confidence interval remaining below zero. Patient Global Impression of Change favored PT-TENS at 120 (72%) versus 86 (51%), and 30% or great
- Platelet-Rich Plasma May Function as a Bioregulatory System in Soft-Tissue Remodelinghttps://reachmd.com/news/platelet-rich-plasma-may-function-as-a-bioregulatory-system-in-soft-tissue-remodeling/2487555/A newly published review in Aesthetic Plastic Surgery examines the evolving understanding of platelet-rich plasma (PRP), suggesting that its role in soft-tissue repair extends beyond conventional growth-factor delivery and may involve broader regulation of the tissue microenvironment.
- Mental Health Burden in Long-Term Survivors of Childhood and Young Adult Cancerhttps://reachmd.com/news/mental-health-survivors-childhood-young-adult-cancer/2487550/Key Takeaways First mental health events were more common in five-year survivors of cancer diagnosed before age 40 than in matched comparators without a cancer history. Higher incidence in survivors was observed across follow-up intervals, with hazard
- Conditional Medicaid Expansion and Mental Healthhttps://reachmd.com/news/conditional-medicaid-expansion-and-mental-health-in-georgia/2487534/Key Takeaways Compared with neighboring nonexpansion states, low-income adults in Georgia reported more days in the past month when mental health was not good after Pathways began. A second primary outcome also moved in the same direction, with more re
- Tiger Aesthetics Launches BioBody and BioDerma Divisions to Expand Aesthetics Market Reachhttps://reachmd.com/news/tiger-aesthetics-launches-biobody-and-bioderma-divisions-to-expand-aesthetics-market-reach/2487530/Tiger Aesthetics Medical™ has announced a new commercial structure centered on 2 dedicated divisions—BioBody™ and BioDerma™—as the company seeks to accelerate growth and expand market penetration across medical aesthetics. According to the company, the reorganization is supported by increa
- RRS® HA LONG LASTING Earns Top Skin Revitalization Honor at AMWC 2026https://reachmd.com/news/rrs-ha-long-lasting-earns-top-skin-revitalization-honor-at-amwc-2026/2487529/Skin Tech Pharma Group announced that RRS® HA LONG LASTING has been awarded Best Injectable in the Skin Revitalization category at the AMWC Aesthetic Medicine Awards 2026, a recognition presented during the Aesthetic & Anti-Aging Medicine World Congress (AMWC). The award recognizes RRS
- SNAP Trial Reports Cefazolin Safety And Effectiveness In MSSA Bacteremiahttps://reachmd.com/news/snap-trial-reports-cefazolin-safety-and-effectiveness-in-mssa-bacteremia/2487527/Key Takeaways Cefazolin was reported to perform at least as well as cloxacillin or flucloxacillin for MSSA bacteremia. Cefazolin was associated with fewer side effects and fewer cases of acute kidney injury in the reported comparison. The find
- Exa-Cel in Children With Transfusion-Dependent Beta Thalassemia or Sickle Cell Diseasehttps://reachmd.com/news/exa-cel-in-children-with-transfusion-dependent-beta-thalassemia-or-sickle-cell-disease/2487526/Key Takeaways All evaluable children in the beta thalassemia cohort became transfusion independent, and all evaluable children in the sickle cell disease cohort had no severe vaso-occlusive crises. The findings came from two ongoing phase 3, open-label
- Cellese Appoints Christopher Hausman as CEO to Lead Next Phase of Growth in Regenerative Aestheticshttps://reachmd.com/news/cellese-appoints-christopher-hausman-as-ceo-to-lead-next-phase-of-growth-in-regenerative-aesthetics/2487520/Cellese Inc., the regenerative aesthetics company behind the AnteAGE® skincare brand, has appointed Christopher Hausman as Chief Executive Officer, the company announced. Hausman joins Irvine, California-based Cellese with more than 3 decades of experience in the aesthetics, skincare, dent